Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Novel Use of Restasis and PROSE Devices

NCT04735510
Conditions
Ocular Surface Disease
Interventions
cyclosporine ophthalmic emulsion 0.05%
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Needham, Massachusetts
Conditions
Dry Eye Disease
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Azusa, California • Hemet, California + 33 more
Conditions
Dry Eye Disease
Interventions
TL-925, Placebo
Drug · Other
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • La Mesa, California + 15 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

NCT04918823
Conditions
Ocular Surface Disease
Interventions
Restasis
Drug
Lead sponsor
Boston Sight
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Conditions
Pterygium
Interventions
CBT-001, Vehicle
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more
Conditions
Photoaging, Wrinkle
Interventions
Radiofrequency Microneedling, Facial Cleanser, Facial Moisturizer, Sunscreen
Procedure · Other
Lead sponsor
Revision Skincare
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Conditions
Dry Eye Syndrome
Interventions
Optive, Soothe, New Emulsion, Soothe, New Emulsion, Optive, New Emulsion, Optive, Soothe
Other
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Fullerton, California
Conditions
Contact Lens Wearers With Dry Eye Syndrome
Interventions
cyclosporine ophthalmic emulsion
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Laguna Hills, California + 11 more
Conditions
Dry Eye
Interventions
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Town and Country, Missouri
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Restasis for Treatment of Brittle Nails

NCT00986427
Conditions
Brittle Nails
Interventions
Restasis (cyclosporine ophthalmic emulsion) 0.05%, Refresh® Dry Eye therapy
Drug
Lead sponsor
Julian M. Mackay-Wiggan
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Vernal Keratoconjunctivitis
Interventions
NOVA22007 ''Ciclosporin'', Placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
4 Years to 18 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Glendale, California • Irvine, California • Rancho Cordova, California + 1 more
Conditions
Dry Eye Disease
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Newport Beach, California • Colorado Springs, Colorado • Indianapolis, Indiana + 1 more
Conditions
Keratoconjunctivitis Sicca
Interventions
Lotemax, Restasis, Soothe® Lubricant Eye Drops
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Irvine, California
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine 0.05% Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Conditions
Abscess
Interventions
Methylene Blue, Lipid Emulsion, Insertion of optical fiber, Laser Illumination (pre-defined dose), Optical Spectroscopy Measurement, Laser Illumination (patient-specific dose), Standard of care abscess drainage
Drug · Device · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Rochester, New York
Completed Phase 4 Interventional Results available

Effect of Cequa™ in Subjects With Dry Eye Disease

NCT04357795
Conditions
Dry Eye Disease
Interventions
CequaTM (Cyclosporine 0.09%) ophthalmic solution
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Fort Myers, Florida • Jacksonville, Florida • Panama City, Florida + 2 more
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Conditions
Pinguecula
Interventions
CBT-004
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Glendale, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

NCT01276223
Conditions
Dry Eye Disease
Interventions
Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Dry Eye
Interventions
ORB Ocular Emulsion, SootheXP Emollient (Lubricant) Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
Interventions
Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%
Drug
Lead sponsor
Edward J. Holland
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina
Conditions
Diabetic Macular Edema
Interventions
NOVA63035 "Corticosteroid"
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana